Depression Screening/Mental Health Market Racing to a Heightened Growth of 4.5% by 2023

Market Research Future adds new report of “Depression Screening/Mental Health Market- Global Forecast till 2023” it contains Company information, geographical data and Table of Content

Competitive Analysis:

Some of the key players in this market are: Alkermes (Republic of Ireland), ALLERGAN (Republic of Ireland), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), Otsuka Holdings Co.,Ltd. (Japan), Pfizer Inc. (US), and others.

Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/3806

Market Highlight:

Depression and mental health are the major health issues across the globe. Increasing prevalence of various mental disorder, social and environmental changes, and changing lifestyle are major drivers for the market growth. Rising funding for R&D and clinical trials are also driving the growth for the market. Increasing awareness of disorders and treatments, rapid adoption of new therapies and treatments, and technological advancement are key drivers for the market.

The global depression screening/mental health market is growing at the CAGR of ~4.5% during the forecast period and expected to reach US$ 11245.6 million by 2023.

Market Segments:

Global depression screening/mental health market has been segmented on the basis of disorder which comprises of anxiety, mood disorders, depression, bipolar behavior, psychosis, eating disorders, impulse control & addiction disorders, personality disorders, stress response syndromes, dissociative disorder, somatic symptom disorder, factitious disorder, and others. Anxiety is further sub-segmented into Generalized Anxiety Disorder (GAD), panic disorder, phobias, Obsessive-Compulsive Disorder (OCD), Post-Traumatic Stress Disorder (PTSD). Mood disorder is further sub-segmented into dysthymia, substance-induced mood disorder, major depression, and others. Depression is further sub-segmented into atypical depression, chronic depression, melancholic depression, catatonic depression, Seasonal affective disorder (SAD), and others. Bipolar disorder is further sub-segmented into bipolar I disorder, bipolar II disorder, cyclothymic disorder, and others. Psychotic disorder is further sub-segmented into schizophrenia, delusional disorder, and others. Eating disorder is further sub-segmented into anorexia nervosa, binge eating disorder, bulimia nervosa, and others. Impulse control and addiction disorder is further sub-segmented into intermittent explosive disorder, pyromania, kleptomania, and others. Personality disorders include various traits such as emotional & impulsive, suspicious, anxious, and others. Dissociative disorder is sub-segmented into dissociative amnesia, dissociative identity disorder, depersonalization- derealization disorder, and others. Somatic symptom disorder somatization disorder, conversion disorder, hypochondriasis, factitious disorder, body dysmorphic disorder, and others. Factitious disorder is further sub-segmented into factitious disorder with mostly psychological symptoms, factitious disorder with mostly physical symptoms, factitious disorder with both psychological and physical symptoms, and others.

On the basis of diagnosis, the market has been segmented into psychological test, Lab tests, Depression Screening Tests and others. Psychological test is further sub-segmented into intelligence tests, attitude tests, personality tests, achievement tests, and others. Lab tests sub-segmented into blood tests, CT scan or MRI of the brain, Electroencephalogram (EEG), Electrocardiogram (ECG). Depression Screening Tests includes Patient Health Questionnaire-10 (PHQ-10), Beck Depression Inventory (BDI), Zung Self-Rating Depression Scale, Center for Epidemiologic Studies-Depression Scale (CES-D), and Hamilton Rating Scale for Depression (HRSD).

On the basis of treatment, the market has been segmented into medication, psychotherapy, brain-stimulation treatments, hospitalization, substance abuse treatment, and others. Medication includes anti-anxiety medications, antidepressants, antipsychotic medications, mood-stabilizing medications, opioid antagonists, atypical neuroleptics, glutamatergic agents, and others. Psychotherapy is further sub-segmented into cognitive and behavioural therapies, humanistic therapies, psychoanalytical and psychodynamic therapies, and others. Brain-stimulation treatments includes repetitive Transcranial Magnetic Stimulation (rTMS), Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Vagus Nerve Stimulation (VNS), and others.

On the basis of end user, it is segmented into hospitals & clinics, medical research centers, academic institutes, and others.

Browse Report Details @ https://www.marketresearchfuture.com/reports/depression-screening-mental-health-market-3806

Regional analysis of global depression screening/mental health market:

Considering the global scenario of the market, the Americas hold the largest market share due to various factors such as availability advanced diagnostic and treatment, funding for research, increasing number of patients with mental illness and related disorders. Increasing stress and changing lifestyle is driving the growth for European Depression Screening/Mental Health market. It is the second largest where the west European countries are dominating the largest market share. Increasing prevalence of mental disorders, rapidly changing healthcare sector, and increasing healthcare spending are major growth drivers for Asia Pacific Depression Screening/Mental Health market. Middle East & Africa (ME&A) is likely to have a limited growth in the market due to some major factors like low knowledge of disorders and treatments, low-income, and limited access to healthcare facilities.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:
Akash Anand,
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
+1 646 845 9312
Email: sales@marketresearchfuture.com

This release was published on openPR.